1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,720 | 9,810 | 26.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 113 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| 04.12.25 | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 128 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen | |
| 28.11.25 | Devyser Diagnostics AB: Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test | 769 | GlobeNewswire (Europe) | Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's PrenatalDetect RHD test (CPT 0536U) at $192. The non-invasive... ► Artikel lesen | |
| 25.11.25 | Devyser Diagnostics AB: Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study | 305 | GlobeNewswire (Europe) | Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution... ► Artikel lesen | |
| 05.11.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2025 | 146 | GlobeNewswire (Europe) | "I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major companies in... ► Artikel lesen | |
| 04.11.25 | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 274 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09.25 | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 149 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 15.08.25 | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08.25 | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 216 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06.25 | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 220 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 444 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04.25 | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 314 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02.25 | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 306 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02.25 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 452 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01.25 | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 256 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 84,70 | -0,05 % | Anteris Technologies Global Corp.: Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises | MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed... ► Artikel lesen | |
| HCA HEALTHCARE | 395,60 | -0,53 % | HCA Healthcare Q4 2025 Earnings Preview | ||
| LANTHEUS | 57,36 | +0,49 % | Lantheus Holdings, Inc.: Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies | BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians... ► Artikel lesen | |
| ENVISTA | 20,400 | 0,00 % | Mizuho stuft Envista Holdings wegen Wachstumsaussichten auf "Neutral" hoch | ||
| CAREDX | 17,600 | +0,57 % | CareDx, Inc.: CareDx präsentiert neue IVD-Produkte und IVDR-Zertifizierung für AlloSeq Tx und QTYPE bei der Jahrestagung 2025 der American Society of Histocompatibility & Immunogenetics | Festigung der weltweiten Führungsrolle bei der HLA-Typisierung von Spenderorganen und Transplantatempfängern
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company ein führendes Unternehmen auf dem... ► Artikel lesen | |
| GT BIOPHARMA | 0,690 | -3,09 % | GT Biopharma, Inc. - S-1, General form for registration of securities | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports First Quarter Fiscal Year 2026 Results | Reports 21% Increase in ARR to $21.3 Million, Strong Growth in Net Income, Adjusted EBITDA and Operating Cash Flow
HENDERSON, Nev., Nov. 13, 2025 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | The Versailles Economic Court has opted for the takeover bid within the context of a sales plan submitted by CARMAT SAS and approved the sale plan1 of CARMAT SA to CARMAT SAS
Regulatory News:
CARMAT... ► Artikel lesen | |
| CHEMOMETEC | 89,05 | -0,34 % | Chemometec A/S: Growth in revenue and operating profit | Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): (1) SUPPLEMENTAL ANNOUNCEMENT ON DELAY IN PUBLICATION OF THE INTERIM RESULTS AND DELAY IN DESPATCH OF THE 2025 INTERIM REPORT; AND ... | ||
| POLAREAN IMAGING | 0,001 | -100,00 % | Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study | ||
| SIEMENS HEALTHINEERS | 43,290 | -0,02 % | BERENBERG stuft Siemens Healthineers auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Siemens Healthineers auf "Buy" mit einem Kursziel von 54 Euro belassen. 2025 sei ein weiteres durchwachsenes Jahr für den... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,200 | -0,05 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 37,40 Euro auf "Underweight" belassen. Analyst David Adlington nahm am Donnerstagabend in seinem... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 28,780 | +1,48 % | EQS-Adhoc: Carl Zeiss Meditec AG: Q1 GJ 2025/26 Ergebnis deutlich unter Vorjahr - Prognose für GJ 2025/26 wird voraussichtlich nicht erreicht | EQS-Ad-hoc: Carl Zeiss Meditec AG / Schlagwort(e): Quartalsergebnis/Prognoseänderung
Carl Zeiss Meditec AG: Q1 GJ 2025/26 Ergebnis deutlich unter Vorjahr - Prognose für GJ 2025/26... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 40,090 | +1,14 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 9,970 Euro und damit +3,10 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.